Final Safety and Efficacy Results from the CPX-351 Early Access Program (EAP) for Older Patients with High-Risk/Secondary Acute Myeloid Leukemia (sAML)

MLA

Michael Chiarella, et al. “Final Safety and Efficacy Results from the CPX-351 Early Access Program (EAP) for Older Patients with High-Risk/Secondary Acute Myeloid Leukemia (SAML).” Blood, vol. 132, Nov. 2018, p. 1434. EBSCOhost, https://doi.org/10.1182/blood-2018-99-111537.

APA

Michael Chiarella, Emaryn Mancino, Tara L. Lin, S. Eric Rubenstein, Scott R. Solomon, Gail J. Roboz, Gary J. Schiller, Arthur C. Louie, Melissa L. Larson, & Qi An. (2018). Final Safety and Efficacy Results from the CPX-351 Early Access Program (EAP) for Older Patients with High-Risk/Secondary Acute Myeloid Leukemia (sAML). Blood, 132, 1434. https://doi.org/10.1182/blood-2018-99-111537

Chicago

Michael Chiarella, Emaryn Mancino, Tara L. Lin, S. Eric Rubenstein, Scott R. Solomon, Gail J. Roboz, Gary J. Schiller, Arthur C. Louie, Melissa L. Larson, and Qi An. 2018. “Final Safety and Efficacy Results from the CPX-351 Early Access Program (EAP) for Older Patients with High-Risk/Secondary Acute Myeloid Leukemia (SAML).” Blood 132 (November): 1434. doi:10.1182/blood-2018-99-111537.